Peptide Tools for Cancer Research: Pools, Microarrays, TAAs

Cancer

In almost any organ, tumors can develop and the cancerous cells often spread within the body through the blood or the lymphatic system to form metastases. Among the most common cancers are:

Prostate cancer

Breast cancer

Lung cancer

Colon cancer

Skin cancer (melanoma)

Tumor Antigens & Peptides

Tumor associated antigens are expressed by tumor cells and can be recognized by the host's immune system either by immune cells or by antibodies. Although tumor antigens are larger proteins, the detected T-cell epitopes are short peptides. In contrast, antibody epitopes can be linear, represented by relatively short peptide stretches, or they depend on a certain protein conformation that requires longer peptide sequences for proper interaction.

CD8+ cytotoxic T cells

8 - 10 aa

MHC I

Peptide PoolsPeptide LibrariesAntigen Peptides

CD4+ T cells

12 - 18 aa

MHC II

Antibodies

small peptide epitopes

MHC independent

Peptide MicroarraysPeptide ELISA

Peptides as Radiosensitizers for Radiotherapy

Chelate DOTA Peptides

Peptide Products & Services for Cancer Research

Filter products

Assay Services

B-cell Immunity

Bone-healing

Cancer biomarker research

Drug delivery

Enzymology

Nuclear medicine

Protein-protein-interaction

Proteomics

T-cell immunity

Antigen Peptides

Bone-Healing Peptides

Cancer peptides

Cancer peptides Non-RGD

Cell-Penetrating Peptides

Custom Peptides

Enzyme Substrate Arrays

Micro-Scale Peptides

PepMix Collections

PepMix Pan Select Peptide Pools

PepMix Peptide Pools

PepMix Peptide Pools Controls

PepMix Peptide Pools Infections

PepMix Peptide Pools TAA

PepMix Peptide Pools other Antigens

PepMix Ultra Peptide Pools

PepStar Peptide Microarrays

Single Peptide

SpikeMix™ for Targeted Proteomics

SpikeTides™ Reference Peptides

Adenocarcinoma

Albinism

Alzheimer's disease

Arthritis

Autoimmune disease

Blood coagulation

Brachyury Mutation

Burkitt's lymphoma

Cancer

Celiac disease

Cell motility

Control

Cystic Fibrosis

Diabetes

Diabetes mellitus

Epithelium

Gastric cancer

Gene therapy

Glioma

Granulomatosis

Hepatitis

Hepatocellular carcinoma

Immune checkpoint

Immunogenic

Inflammation

Kinase

Leukemia

Lyme disease

Lymphoma

Major depression

Malignant genital cancers

Melanoma

Metabolism

Microphthalmia syndromic type 3

Multiple sclerosis

Neurodegeneration

Ovarian cancer

Phosphatase

Respiratory disease

Respiratory infection

Vitiligo

Wegener's Disease

Wilms tumor 1

non-Hodgkin lymphoma

Arabidopsis thaliana (Mouse-ear cress)

Artificial

Clostridium tetani

Drosophila

Escherichia coli

Human

Mouse

Triticum aestivum

5,6-dihydroxyindole-2-carboxylic acid oxidase

Actin

Actin, alpha skeletal muscle

Alpha-Synuclein

Alpha-fetoprotein

Apelin

Aquaporin-4

Baculoviral IAP repeat-containing protein (BIRC)

CPP

Cancer/testis antigen (NY-ESO)

Cancer/testis antigen 1 (NY-ESO-1)

Cancer/testis antigen 2 (NY-ESO-2)

Carcinoembryonic antigen-related cell adhesion molecule 5

Cellular tumor antigen p53

Claudin-6

Coagulation factor VIII

Cystic fibrosis transmembrane conductance regulator

Cytokines

Cytotoxic T-lymphocyte protein

ErbB-2 receptor tyrosin-protein kinase

Four-jointed box protein 1

G2/mitotic-specific cyclin-B1

GTPase KRas

Glycoprotein

HLA class II antigen

HLA class I antigen

HLA class I histocompatibility antigen, A-36 alpha chain

Heat shock protein

Histones

Homeobox protein Nkx-3.1

Hyaluronan mediated motility receptor

Insulin

Kallikrein-2

Kinases

Kita-kyushu lung cancer antigen 1

L-dopachrome tautomerase (Tyrosinase-related protein 2)

Mammaglobin-A

Matrilysin

Melanocyte protein Pmel 17 (gp100)

Melanoma-associated antigen (MAGE)

Melanoma-associated antigen 10

Melanoma antigen preferentially expressed in tumors (PRAME/OIP4)

Melanoma antigen recognized by T-cells 1 (MART-1)

Mesothelin

Metalloreductase STEAP1

Minor histocompatibility protein HA-1

Mucin

Mucin-1

Mucin-13

Myc proto-oncogene protein

Myelin-oligodendrocyte glycoprotein

Myelin basic protein

Myeloblastin (PRTN3)

Other

Placenta-specific protein 1

Programmed cell death 1 ligand

Programmed cell death protein

Progranulin

Prostate-specific antigen

Prostate-specific membrane antigen

Prostate stem cell antigen

Prostatic acid phosphatase (PAP)

Protein SSX2

Protein SSX4

Putative tyrosine-protein phosphatase TPTE

Radio sensitizer

Regulator of G-protein signaling 5

Selected proteins

Serine/threonine-protein kinase B-raf

Stromelysin-3 (MMP11)

Synaptonemal complex protein 1

TCRgamma alternate reading frame protein

Telomerase reverse transcriptase

Tetanus Toxin

Thymidylate synthase

Transcription factors/activators

Tyrosinase

Wilms tumor protein

No

Antibody Response Profiling

Custom PepMix™ Peptide Pools

Custom PepStar™ Peptide Microarrays

(Arg)9 Nona-D-Arginine Peptide

US$1,042.60

(Arg)9 Nona-L-Arginine R9 Peptide

US$416.00

(Lys)9 Peptide Nona-Lysine

US$187.20

[Pyr 1]-Apelin-13, CAS 217082-60-5

US$186.52

Acetylcholine receptor subunit alpha 164-176, MKLGTWTYDGSVV

US$178.10

Antennapedia (43-58) - Penetratin Peptide

US$231.40

Antigen Peptide ERBB2 H-2 Kd (TYLPTNASL)

Clinical Peptides

Cellular Immune Response Profiling

Immune monitoring

Immunotherapy

Epitope discovery

Ready-made peptide pools for TAAs such as Erb/Her2 and MAGE and for tumor viruses such as HPV

Custom PepMix™ peptide pools

Vaccine development

High-throughput T-cell epitope discovery

Monitoring of cellular immune response

Clinical trials

Humoral Immune Response Profiling

JPT is the technology leader for peptide microarrays. We offer a range of pre-made catalog peptide microarrays for multiple TAAs and production of customized peptide microarrays. In addition, we provide a modular assay and analysis service using high content peptide microarrays, multiwell microarrays and peptide ELISA.

Immune monitoring of humoral response

Profiling of cancer specific samples or antibodies

Detection of epitopes and epitope spreading

Vaccine target identification

Catalog Peptide Microarray for TAAs such as Erb/Her2 and Survivin and for tumor viruses

Tailored PepStar™ Peptide Microarrays: you define content and layout

Cancer & Epigenetics

Cancer Proteomics

References

Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5Gan et al., Journal of Translational Medicine Products used: PepMix™ Human (FJX1), PepMix™ Human (MAGED4)

Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trialGeboers et al., Journal for Immunotherapy of Cancer (2025) - PMID: 40139834Product used: PepMix™ Human (Survivin), PepMix™ Human (WT1/WT33), CEFT Pool

UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunityLaheurte et al., Cell Reports Medicine (2025) - PMID: 40543509 Products used: PepMix™ Human (NY-ESO-1), PepMix™ HIV-1 (ENV) Ultra

Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruptionLopez et al., Breast Cancer Research (2025) - PMID: 39920833Product used: Custom Peptides

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialLopez et al., Nature Medicine (2025) - PMID: 39762422Product used: Custom PepMix

Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasisPinho et al., Cell Reports Medicine (2025) - PMID: 40730190Products used: PepMix™ Human (ErbB2_ECD), PepMix™ Human (ErbB2_ICD), PepMix™ Human (ACTL8), PepMix™ Human (PLAC1), PepMix™ Human (Prame/OIP4)

Preclinical evaluation of [225Ac]Ac-PSMA-617 and in vivo effect comparison in combination with [177Lu]Lu-PSMA-617 for prostate cancerSavio et al., Nuclear Medicine and Biology (2025) - PMID: 40513471Products used: Chelate DOTA Peptides

Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical StudiesSun et al., Advanced Science (2025) - PMID: 41134065Product used: PepMix™ Human (PD-L1) & other PepMix™ TAAs

Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trialThibaudin et al., Signal Transduction and Targeted Therapy (2025) - PMID: 39820336Products used: PepMix™ Human (NY-ESO-1)

Phase I trial and preclinical data of ACT using neoantigen-reactive TIL for patients with advanced epithelial and ICB-resistant solid cancersPalomero et al., Immuno-oncology & technology (2024) - PMID: 39911162Products used: Custom Peptides Synthesis

Use of MS-GUIDE for identifcation of protein biomarkers for risk stratifcation of patients with prostate cancerGoetze et al., Clinical Proteomics (2022) - PMID : 35477343

Transcriptome profling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell lineVasiliou et al., Clinical Proteomics (2022)

Diagnosing pleural efusions using mass spectrometry‑based multiplexed targeted proteomics quantitating mid‑to high‑abundance markers of cancer, infection/infammation and tuberculosisRobak et al., Scientific Reports (2022)

Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigensWeber et al., Nature Biotechnology (2022)

CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancersJin et al., Nature Biomedicical Engineering (2022)

CD206+ tumor-associated macrophages cross-present tumor antigen and drive anti-tumor immunityModak et al., JCI Insight (2022) - PMID: 35503656Products used: Antigen Peptide NY-ESO-1 - HLA-A*0201 (SLLMWITQC)

Linear DNA amplicons as a novel cancer vaccine strategyConforti et al., BioRxiv (2022)

Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic CancersJenny Dunn et al., Cancers (2022) - PMID: 35326747

Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancerMatsuzaki et al., Oncoimmunology (2022) - PMID: 35003898Products used: PepMix™ Human (Claudin-6)

The human CXCR3 chemokine system in early differentiated CD8+ T cell function and solid tumorsTino Vollmer, Dissertation (2022)

New Monoclonal Antibodies That Recognize an Unglycosylated, Conserved, Extracellular Region of CD44 in Vitro and in Vivo, and Can Block TumorigenesisDaniel F. Lusche et al., PLOS ONE (2021) - PMID: 33891595

Identification of Potential Salivary Biomarker Panels for Oral Squamous Cell CarcinomaAnu Jain et al., Sci Rep, (2021)

Transcriptional Programs of Neoantigen-Specific TIL in Anti-PD-1-Treated Lung CancersCaushi, J.X. et al., Nature, (2021)

Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor ModelBassel Akache et al., Pharmaceutics, (2021)

Reversion Analysis Reveals the in Vivo Immunogenicity of a Poorly MHC I-Binding Cancer NeoepitopeHakimeh Ebrahimi-Nik et al., Nat Commun, (2021)

Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in OncologyNatalia Sacilotto et al., ACS Pharmacol Trans Sci, (2021)

Dysfunction of Exocytosis Causes Catecholamine Hypersecretion in Patient With PheochromocytomaSébastien Houy et al., BioRxiv, (2021)

Screening for New Peptide Substrates For the Development of Albumin Binding Anticancer Pro-Drugs That Are Cleaved By Prostate-Specific Antigen (PSA) to Improve The Anti Tumor EfficacyBakheet E.M. et al., Biochemistry and Biophysics Reports (2021) - PMID: 33718631

Proteomic Analysis of Urinary and Tissue‐Exudative Extracellular Vesicles to Discover Novel Bladder Cancer BiomarkersEisuke Tomiyama et al., Cancer Sci, (2021)

Profiling the HCV Immune Response in Patients With Chronic Liver Diseases and Hepatocellular Carcinoma by Peptide Microarray AnalysisAnna Lucia Tornesello et al., Curr Med Chem, (2021)

NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant CancersAtsushi Takatori et al., Front Oncol, (2021)

Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target AntigensAdam S Kibel et al., J Natl Cancer Inst. (2021) - PMID: 33630063

Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by ImmunizationAnna Przybyla et al., Cancers (Basel) (2021) - PMID: 33435427

Identification of Novel HLA-Restricted Preferentially Expressed Antigen in Melanoma Peptides to Facilitate Off-The-Shelf Tumor-Associated Antigen-Specific T-Cell TherapiesMaja Stanojevic et al., Cytotherapy, (2021)

Oncolytic Measles Virus Therapy Enhances Tumor Antigen-Specific T-Cell Responses in Patients With Multiple MyelomaNandakumar Packiriswamy et al., Leukemia (2020) - PMID: 32327728

Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (CIC/CRI)Leah S. Price et al., Journal of Quantitative Cell Science (2020) - PMID: 33090656

Microwave Ablation Enhances Tumor‑Specific Immune Response In Patients With Hepatocellular CarcinomaKatharina Leuchte et al., Cancer Immunology, Immunotherapy (2020) - PMID: 33006650

Identification of Key Biomarkers in Bladder Cancer: Evidence from a Bioinformatics AnalysisChuan Zhang et al., Diagnostics (2020) - PMID: 31991631

An Unbiased Approach to Defining Bona Fide Cancer Neoepitopes That Elicit Immune-Mediated Cancer RejectionCory A. Brennick et al., J Clin Invest. (2020) - PMID: 33320837

Identification of two HLA-A*0201 Immunogenic Epitopes of Lactate Dehydrogenase C (LDHC): Potential Novel Targets for Cancer ImmunotherapyRemy Thomas et al., Cancer Immunology, Immunotherapy (2020) - PMID: 31932876

Modified Natural Killer Cells And Natural Killer Cells Lines Targeting Tumour CellsMichael Eamon Peter O'dwyer et al., United States Patent Application 20200392458 (2020) - PMID: n.a.

Adoptive Immunotherapy Using PRAME-Specific T Cells in MedulloblastomaDr. Biagio De Angelis et al., Immunology And Immunopathology (2020) - PMID: 29615432

In Vitro Comparison of the Effects ofImatinib and Ponatinib on ChronicMyeloid Leukemia Progenitor/Stem CellFeaturesIgnazia Tusa et al., Targeted Oncology (2020) - PMID: 32780298

Globally Altered Epigenetic Landscape and Delayed Osteogenic Differentiation in H3.3-G34W-Mutant Giant Cell Tumor of BonePavlo Lutsik et al., Nature (2020) - PMID: 33110075

An HER2 DNA Vaccine with Evolution-Selected Amino Acid Substitutions Reveals a Fundamental Principle for Cancer Vaccine Formulation in HER2 Transgenic MiceJones et al, Cancer Immunology, Immunotherapy (2019)

Natural T Cell Autoreactivity to Melanoma Antigens: Clonally Expanded Melanoma-Antigen Specific CD8 + Memory T Cells Can be Detected in Healthy HumansAnna Przybyla et al, Cancer Immunology, Immunotherapy (2019)

Proteome-Wide Onco-Proteogenomic Somatic Variant Identification in ER-Positive Breast CancerDimitrakopoulos et al, Clinical Biochemistry (2019)

Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: a Mouse to Human Translational StudyCrosby et al, Clinical Cancer Research (2019)

Rapalog Combined with CCR4 Antagonist Improves Anticancer Vaccines EfficacyBeziaud et al, International Journal of Cancer (2018)

CD11c+ MHCIIlo GM-CSF-Bone Marrow-Derived Dendritic Cells act as Antigen Donor Cells and as Antigen Presenting Cells in Neoepitope-Elicited Tumor Immunity Against a Mouse FibrosarcomaEbrahimi-Nik et al, Cancer Immunol Immunotherapy (2018)

Tel-eVax: a Genetic Vaccine Targeting Telomerase for Treatment of Canine LymphomaImpellizeri et al, Journal of Translational Medicine (2018)

An MRM-Based Cytokeratin Marker Assay as a Tool for Cancer Studies: Application to Lung-Cancer Pleural EffusionsPerzanowsk et al., Proteomics Clin Appl. (2018) - PMID: 29352525

Testimonials

Application Notes